登录查看更多内容

Antibody-based delivery of TNF to the tumor neo-vasculature potentiates the therapeutic activity of a peptide anti-cancer vaccine

Tim Fugmann

Chief Scientific Officer and Co-Founder

发布日期: 2018年11月20日

+ 关注

In our recent publication in Clinical Cancer Research, we could demonstrate that the targeted delivery of TNF to CT26 tumors strongly synergizes with the immuno-dominant retroviral AH1 peptide vaccine.

#immunooncology #precisionmedicine #immunopeptidomics #cancer #vaccine #cancervaccine

要查看或添加评论，请登录

Tim Fugmann的更多文章

Genomic correlates of response to immune checkpoint blockade

2019年3月19日

Genomic correlates of response to immune checkpoint blockade

Fantastic review on genomic correlates of response to immune checkpoint blockade including peptide-MHC-T cell…
Resolution of inflammation as a way to cure inflammatory conditions?

2019年2月21日

Resolution of inflammation as a way to cure inflammatory conditions?

Great review on all stages of an inflammatory process from initiation and acute inflammation to its resolution with…
Immunotherapy awarded Nobel price

2018年10月1日

Immunotherapy awarded Nobel price

James Allison and Tasuku Honjo awarded the Nobel price in Medicine for the discovery of anti-cancer checkpoint blocking…
New deeplearning-based peptide-HLA binding prediction

2018年9月20日

New deeplearning-based peptide-HLA binding prediction

Tensor flow-based deep learning for prediction of peptide-HLA binding and comparison to established software such as…

1 条评论
NK cells can mediate effects of anti PD-1/PD-L1 therapy

2018年9月12日

NK cells can mediate effects of anti PD-1/PD-L1 therapy

In a recent study in JCI, authors report strong contribution of NK cells to successful anti PD-1/PD-L1 therapy in mouse…
Increased affinity to ALCAM homes T cells to glioblastoma

2018年9月10日

Increased affinity to ALCAM homes T cells to glioblastoma

Very interesting way to enhance the T cell homing to glioblastoma tumors. The T cells were engineered to target Her2…
Abberant splicing more common in cancer

2018年8月11日

Abberant splicing more common in cancer

ETH scientists just published a paper in Cancer Cell which demonstrates that abberant splicing in cancer is more…
New study linking expression of MHC complexes and response after CTLA-4 blockade

2018年7月19日

New study linking expression of MHC complexes and response after CTLA-4 blockade

A study from the Dana Farber Cancer Institute revealed that the clinical efficacy of anti-CTLA-4 drugs like ipilimumab…
Characterization of the Soluble HLA Peptidome for Predicting Response to Immunotherapy

2018年6月6日

Characterization of the Soluble HLA Peptidome for Predicting Response to Immunotherapy

We will be presenting our view on the prediction of response to treatment at this year's Biomarkers and Immuno-oncology…
Join us at ASMS 2018 in San Diego

2018年6月1日

Join us at ASMS 2018 in San Diego

The american society of mass spectrometrie's annual conference returns to the sunny beaches of San Diego. Join as at…

See all articles

Antibody-based delivery of TNF to the tumor neo-vasculature potentiates the therapeutic activity of a peptide anti-cancer vaccine

Tim Fugmann

Chief Scientific Officer and Co-Founder

In our recent publication in Clinical Cancer Research, we could demonstrate that the targeted delivery of TNF to CT26 tumors strongly synergizes with the immuno-dominant retroviral AH1 peptide vaccine.

Tim Fugmann的更多文章

社区洞察

其他会员也浏览了

Iruplinalkib for locally advanced or metastatic ALK+ NSCLC

Intravenous Vitamin C's Mechanisms of Action in Cancer: Exploring the Evidence

Restoring the Guardian of the Genome to Fight Tumors

Harnessing the Immune System to Diagnose and Treat Cancer

Tackling the Problem of Resistance in Chemotherapy

T Cell Therapy, Revolutionizing Cancer Treatment

Tumour-infiltrating lymphocyte cancer therapy nears FDA finish line

How can we optimize the endocrine treatment of advanced HR+/HER2- breast cancer?

Let's combine PI3Kβ inhibitors with immunotherapy for the treatment of PTEN-deficient breast cancer:

New publication on a new strategy to target metastatic Cancer Stem Cells in gastric cancer

In our recent publication in Clinical Cancer Research, we could demonstrate that the targeted delivery of TNF to CT26 tumors strongly synergizes with the immuno-dominant retroviral AH1 peptide vaccine.

Tim Fugmann的更多文章

Genomic correlates of response to immune checkpoint blockade

Resolution of inflammation as a way to cure inflammatory conditions?

Immunotherapy awarded Nobel price

New deeplearning-based peptide-HLA binding prediction

NK cells can mediate effects of anti PD-1/PD-L1 therapy

Increased affinity to ALCAM homes T cells to glioblastoma

Abberant splicing more common in cancer

New study linking expression of MHC complexes and response after CTLA-4 blockade

Characterization of the Soluble HLA Peptidome for Predicting Response to Immunotherapy

Join us at ASMS 2018 in San Diego

社区洞察

其他会员也浏览了

Iruplinalkib for locally advanced or metastatic ALK+ NSCLC

Intravenous Vitamin C's Mechanisms of Action in Cancer: Exploring the Evidence

Restoring the Guardian of the Genome to Fight Tumors

Harnessing the Immune System to Diagnose and Treat Cancer

Tackling the Problem of Resistance in Chemotherapy

T Cell Therapy, Revolutionizing Cancer Treatment

Tumour-infiltrating lymphocyte cancer therapy nears FDA finish line

How can we optimize the endocrine treatment of advanced HR+/HER2- breast cancer?

Let's combine PI3Kβ inhibitors with immunotherapy for the treatment of PTEN-deficient breast cancer:

New publication on a new strategy to target metastatic Cancer Stem Cells in gastric cancer